There are more innovative ways to manufacturing new vaccines in demand, which consists of implementing more effective techniques of vaccine propagation.
For example, cell-based flu vaccines have been recognized as a substitute to traditional egg-based vaccines. These vaccines are quicker and easier to manufacture to address issues associated with egg allergies. Please refer to http://acggp.com/industry-watch-blog/ for our previous Industry blog post on cell-based flu vaccine.
Egg-based flu vaccines have been condemned for its incompetency for many reasons, which includes post antibody-antigen binding affinity.
Live recombinant vaccines employ attenuated viruses (or bacterial strains) as vectors for immunogens which acts as a substitute. Recombinant vaccines are faster to manufacture and more efficient and have very little adverse effects compared to traditional substitutes.
Recombinant and cell-based vaccines are more appropriate to reacting to a pandemic, due to its ability to be manufactured faster.
DNA vaccines are a potential opportunity for R&D development. DNA vaccines remove the DNA which encodes a specific antigen and injects it directly into the muscle or skin.
DNA vaccines are simple to manufacture and deliver long-term immunity with very little adverse effects. They are inexpensive compared to other vaccines and convenient to transport which helps to meet the requirements of those in developing countries.
DNA vaccines have not yet been discovered to create a immune response which is very effective to facilitate further development requirements in this area. Adjuvants support DNS to enter cells or aim it towards particular cells could be suggested to help the efficacy of vaccines.